Effect of traditional Chinese medicine Bailing capsule on renal anemia in maintenance hemodialysis patients: A protocol for systematic review and meta-analysis. Issue 15 (15th April 2022)

• Record Type: Journal Article
• Authors: Li, Yan-Lin; Cheng, Fang; Chen, Yan; Wang, Jun; Xiao, Zeng-Dong; Li, Bin
• Is Part Of: Medicine. Volume 101:Issue 15(2022)
• Page Start: e29086
• Publication Date: 2022-04-15
• Subjects: Bailing capsule -- end-stage renal disease -- maintenance hemodialysis -- meta-analysis -- renal anemia -- traditional Chinese medicine; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000029086
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: Renal anemia (RA) is one of the most common complications in patients with end-stage renal disease, and it is also one of the reasons for the decline of quality of life and functional status in patients with end-stage renal disease. Traditional treatment methods often fail to achieve satisfactory therapeutic effects, so it is very necessary to find effective adjuvant treatment methods. Bailing capsule (BLC), a traditional Chinese medicine, which has been widely used in the treatment of RA in maintenance hemodialysis patients, but a systematic review of the efficacy and safety of this drug is currently lacking. Therefore, this study used meta-analysis to evaluate the efficacy and safety of BLC in the treatment of RA, in order to provide guidance for finding effective auxiliary methods for the treatment of RA in maintenance hemodialysis patients (MHP). Methods: Using the computer to retrieve PubMed, EMbase, Cochrane Library, CNKI, VIP Database, WANFANG Database, SinoMed from 1990 to 2021 and collecting the clinical randomized controlled trial and retrospective cohort study of BLC in the treatment of RA in MHP. Two researchers independently read and screened the literature, followed by evaluating the retrospective cohort studies that met the selection criteria using the Newcastle-Ottawa Scale (NOS) scale. The randomized controlled trial used the Cochrane manual standards to assess the risk of bias, and the RevMan 5.3 software was used to conduct a meta-analysis of the result data. Results: This study will use the method of meta-analysis to evaluate the clinical efficacy and incidence of adverse reactions of BLC in the treatment of RA in MHP through the primary and secondary outcome indicators. Conclusion: The results of this study will help clinicians find safe and effective adjuvant therapy in the treatment of RA in MHP. OSF registration number: DOI 10.17605/OSF.IO/732KP (https://osf.io/732kp ).